Titlebook: Immunotherapy; Aung Naing,Joud Hajjar Book 2021Latest edition The Editor(s) (if applicable) and The Author(s), under exclusive license to

選民

書目名稱Immunotherapy影響因子(影響力)




書目名稱Immunotherapy影響因子(影響力)學(xué)科排名




書目名稱Immunotherapy網(wǎng)絡(luò)公開度




書目名稱Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Immunotherapy被引頻次




書目名稱Immunotherapy被引頻次學(xué)科排名




書目名稱Immunotherapy年度引用




書目名稱Immunotherapy年度引用學(xué)科排名




書目名稱Immunotherapy讀者反饋




書目名稱Immunotherapy讀者反饋學(xué)科排名

試驗

Resistance to Immunotherapy: Mechanisms and Means for Overcoming,r over the course of treatment, and many patients with PD-L1-expressing tumors do not respond to PD-(L)1 blockade. In addition, while some malignancies exhibit inherent resistance to treatment, others develop adaptations that allow them to evade antitumor?immunity after a period of response. It is c

輕打

青石板

Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?,iple clinical settings. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by the FDA either alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 agents. The introduction of these agents in clinical practice

prostate-gland

Landscape of Immunotherapy in Genitourinary Malignancies,itourinary cancers. Immune checkpoint inhibitors have notably improved the treatment outcomes of patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma. In prostate cancer, the role of immunotherapy with checkpoint inhibitors is not yet established except for microsatellit

知識

Immuno-Oncology for Gynecologic Malignancies,s of immunotherapy in other difficult-to-treat malignancies such as metastatic melanoma and advanced lung cancer have led to intense interest in clinical testing of these treatments in patients with gynecologic cancers. Currently, in the realm of gynecologic oncology, the FDA-approved use of immune

expansive

Immunotherapy for Neuro-oncology,eral circumstances unique to the central nervous system (CNS) such as limited space for an inflammatory response, difficulties with repeated sampling, corticosteroid use for management of cerebral edema, and immunosuppressive mechanisms within the tumor and brain parenchyma have posed challenges in

chemical-peel

Immunotherapy in Gastrointestinal Malignancies,ment and subsequent prognosis. The interplay between tumor cells and the local immune microenvironment also varies within each GI malignancy and can portend prognosis and response to therapy. Treatment with immune checkpoint inhibitors has changed the treatment landscape of various solid tumors incl

ENACT

審問,審訊

CAR T Cells,xploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued. During World War II, the accidental sinking of a US naval ship led to a group of sailors developing pancytopenia due to poisoning from mustard gas (nitrogen mustard). The observation prompted wide-scale